Form 4: Cyclo Therapeutics Director William S. Shanahan Reports Acquisition of Shares in Lieu of Cash Compensation

Director William S. Shanahan acquired 25,140 shares of Cyclo Therapeutics common stock in lieu of cash compensation for director services.

Summary

• On February 27, 2025, William S. Shanahan, a director of Cyclo Therapeutics, Inc. (CYTH), acquired 25,140 shares of common stock.
• The acquisition was made in lieu of cash compensation under the issuer's non-employee director compensation policy.
• The grant reflects director compensation for the fourth quarter of 2024 and from January 1, 2025 through March 25, 2025.
• The number of shares was calculated based on a closing price of $0.77 per share on February 26, 2025.
• Following the transaction, Shanahan beneficially owns 173,966 shares of Cyclo Therapeutics common stock.

Sentiment

Score: 6

Explanation: Neutral sentiment as it reports a routine transaction of director compensation. The use of stock instead of cash could be seen as slightly positive for the company's financial health.

Positives

• The acquisition of shares by a director demonstrates confidence in the company.
• Using shares instead of cash preserves the company's cash reserves.

Industry Context

Director compensation in the form of stock is a common practice in the pharmaceutical industry to align the interests of directors with those of shareholders and conserve cash.

Comparison to Industry Standards

• Many small-cap biotech companies like Cyclo Therapeutics use stock options or grants as part of their director compensation packages.
• This practice is similar to companies like BioMarin Pharmaceutical and Sarepta Therapeutics, which also utilize equity-based compensation to attract and retain board members.
• The specific amount and terms of the equity grants vary based on company size, performance, and industry benchmarks.

Stakeholder Impact

• Shareholders may view the director's acceptance of stock in lieu of cash as a positive sign of alignment with their interests.
• The company benefits from preserving cash by issuing stock instead of paying cash compensation.

Key Dates